Introduction: Type 2 diabetes mellitus (T2DM)
CV risk factors, saxagliptin neither increased nor decreased CV risk compared with placebo as assessed by the composite end point of death from CV causes, nonfatal myocardial infarction, or nonfatal stroke. Unexpectedly, more patients in the saxagliptin (3.5%) than in the placebo group (2.8%) were hospitalized for heart failure.
Conclusion:
Saxagliptin demonstrated statistically significant and clinically meaningful improvements in glycemic control and a low risk of hypoglycemia in patients with T2DM. However, this positive profile needs to be tempered by the observation of an increased risk of hospitalization for heart failure in the SAVOR trial. Results from ongoing CV outcome trials with other DPP-4 inhibitors may provide additional data on how best to manage patients with T2DM who are at risk for heart failure.
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INTRODUCTION
Diabetes, both diagnosed and undiagnosed, affects an estimated 382 million people worldwide [1] and 29.1 million people in the United States (US) [2] . Type 2 diabetes mellitus (T2DM) accounts for up to 95% of diagnosed cases of diabetes [2] , and the International Diabetes Federation estimates that 46% of all prevalent cases are undiagnosed [1] . T2DM is strongly associated with obesity, physical inactivity, and dyslipidemia [3] . It is becoming evident that there is also a genetic component to T2DM [4] , and although the genetics are not well understood, individuals of certain racial/ ethnic backgrounds and those with a family history of diabetes are at increased risk for development of T2DM [2, 5] . Despite the availability of various classes of antidiabetes agents, nearly half of patients fail to achieve recommended glycemic targets [6, 7] . Poorly controlled T2DM often leads to microvascular (e.g., retinopathy, neuropathy, and nephropathy) and macrovascular [coronary heart disease, stroke, myocardial infarction (MI)] complications [8] , and cardiovascular (CV) disease is the major cause of death in individuals with diabetes [9] .
It is now recognized that T2DM is a chronic, progressive disease and that multiple organs and hormones contribute to its pathogenesis.
Regulation of glucose homeostasis is tightly controlled by a feedback loop involving pancreatic b-cells, a-cells, and insulin-sensitive tissues such as the liver, muscle, and fat [10] . Impairments in glycemic control are evident long before the diagnosis of overt T2DM [11] . As discussed by DeFronzo [11] , in addition to b-cells, liver, and muscle, pancreatic a-cells (increased glucagon secretion), fat cells (increased lipolysis), gastrointestinal tract (incretin deficiency), kidney (increased glucose reabsorption), and brain (neurotransmitter dysfunction) are involved in the pathogenesis of T2DM (Fig. 1 ). This ''ominous octet'' not only puts into perspective the complexity of T2DM but also presents therapeutic targets to explore to improve glycemic control in T2DM.
Incretin Biology
Drugs that act on the incretin system are among the newer antidiabetes therapies. The incretin effect refers to the observation made more than 50 years ago that oral glucose produced a greater increase in plasma insulin concentrations than did an isoglycemic intravenous glucose infusion [12] . At that time, it was hypothesized that a factor(s) released from the gastrointestinal tract in response to oral glucose could be responsible for increased insulin secretion [12] . Subsequently, it Fig. 1 The complexity of type 2 diabetes pathophysiology. HGP hepatic glucose production. Reproduced with permission from DeFronzo [11] was shown that two intestinal hormones, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), were responsible for the potentiated insulin release in response to nutrient ingestion [13] . GLP-1 and GIP are secreted from cells in the intestine in response to food ingestion and act on pancreatic b-cells via distinct receptors to stimulate the release of insulin in a glucose-dependent manner. In healthy individuals, up to 60% of insulin secretion following a meal is due to the actions of the incretin hormones [14] . GLP-1 also inhibits glucagon secretion from pancreatic a-cells in a glucose-dependent manner, regulates gastric emptying, and acts on the central nervous system to reduce food intake [13] . Although meal-stimulated concentrations of both GIP and GLP-1 are variable (can be normal or elevated) in patients with T2DM [10, 12] , the insulinotropic response to GIP is substantially reduced, whereas the insulinotropic response to pharmacologic doses of GLP-1 is retained. Because the response to GLP-1 remains relatively intact in patients with T2DM, incretin-based therapies have focused on GLP-1 receptor agonists or on prolonging the half-life of endogenous GLP-1 by inhibiting dipeptidyl peptidase-4 (DPP-4), the enzyme responsible for the degradation of GLP-1 and GIP [15] .
Saxagliptin is a DPP-4 inhibitor approved in the US, European Union, and elsewhere for the treatment of T2DM in adults. The objective of this article is to discuss the utility of saxagliptin for the treatment of T2DM by reviewing published efficacy and safety data from clinical trials. 
METHODS

RESULTS
Short-Term (24-Week) Data
Placebo-Controlled Monotherapy Studies with Saxagliptin
Four studies examined the efficacy and safety of saxagliptin (2.5 and/or 5 mg/day) as monotherapy in treatment-naïve adults with T2DM not controlled with diet and exercise alone [16] [17] [18] [19] . In these trials, 24 weeks of saxagliptin treatment was associated with significantly greater reductions in glycated hemoglobin (HbA1c) compared with placebo.
Differences vs placebo in HbA1c reduction ranged from -0.45% to -0.65%. Improvements in fasting plasma glucose (FPG) and postprandial glucose (PPG) measured 120 min after a test meal were also noted in these monotherapy studies. In treatment-naïve patients from India [17] and Asia (approximately 59% Chinese) [18] , saxagliptin improved glycemic measures to a similar extent as seen in patients primarily from Western countries ( Table 2 ).
In patients with T2DM poorly controlled with insulin (±metformin), the addition of saxagliptin increased the proportion of patients reaching HbA1c \7% after 24 weeks (17.3%) compared with placebo (6.7%) [27] .
There were small increases in body weight (B0.4 kg) in both treatment groups. The change in daily insulin dose required by patients to maintain prespecified FPG concentrations was greater in patients receiving placebo (5.0 U/day than in those receiving saxagliptin (1.7 U/day). A similar proportion of patients in the saxagliptin and placebo groups reported hypoglycemic events (18.4% and 19.9%) and confirmed hypoglycemia (5.3% and 3.3%; Table 2 ). In patients with inadequate glycemic control taking metformin plus a sulfonylurea, the addition of saxagliptin (5 mg/day) resulted in a significantly greater reduction from baseline in HbA1c vs placebo (-0.66%) at 24 weeks [28] . The reduction in PPG, but not FPG, was also greater with saxagliptin compared with placebo.
In addition, a greater proportion of patients achieved HbA1c \7% with saxagliptin (30.7%) vs placebo (9.4%; P\0.0001; Table 1 ). There were small changes in body weight with saxagliptin (0.2 kg) and placebo (-0.6 kg).
Reported and confirmed hypoglycemic events were similar in the two treatment groups (Table 2) .
Saxagliptin was also compared with glipizide as add-on therapy to metformin [29] . After 52 weeks of treatment, saxagliptin (5 mg/day) was noninferior to glipizide in reducing HbA1c (-0.74% vs -0.80%; (Table 2) .
Dual Add-On of Saxagliptin and Dapagliflozin to Metformin
In contrast to the traditional sequential addition of single oral antidiabetes agents to metformin, a recent clinical trial assessed the and dapagliflozin/metformin (-2.4 kg), whereas no change was noted in patients on saxagliptin/metformin (Table 3) . Hypoglycemic events were infrequent and similar across treatment groups (1%; Table 2 ).
Long-Term Data
The safety and efficacy of most DPP-4 inhibitors Saxagliptin is the only DPP-4 inhibitor with published data through 4 years of treatment [35] .
In a long-term extension of the saxagliptin add-on to metformin study [21] , HbA1c was reduced from baseline to 154 weeks by 0.4% with saxagliptin 2.5 and 5 mg/day compared with an increase of 0.1% with placebo [35] . Also, a greater proportion of patients achieved HbA1c \7% with saxagliptin (19-24%) than with placebo (13%). In this study and in a long-term extension of the saxagliptin monotherapy study [19] , there were no increases in body weight, no increased risk of hypoglycemia, and no new safety findings for up to 4 years of treatment [35] .
In a long-term extension of the saxagliptin plus metformin initial combination trial [24], the change from baseline to 76 weeks in HbA1c with saxagliptin 5 mg/day plus metformin was -2.31% vs -1.79% with placebo plus metformin, changes that were similar to those seen at 24 weeks [36] . In addition, a greater proportion of patients achieved HbA1c \7% was also observed in a long-term extension of the add-on to TZD study [25] . After 76 weeks of treatment, the change from baseline in HbA1c was -0.59% and -1.09% with saxagliptin 2.5 
Older Patients
In the US, the prevalence of diabetes (diagnosed and undiagnosed) in individuals C65 years of age (25.9%) is almost 3 times higher than that in the general population (9.3%) [2] . Because of the low risk of hypoglycemia and general lack of AEs associated with DPP-4 inhibitors, they may be especially useful for older patients [40] .
A post hoc analysis of data pooled from five 24-week, placebo-controlled trials of saxagliptin and a separate analysis of initial combination therapy of saxagliptin plus metformin vs metformin monotherapy assessed the safety and efficacy of saxagliptin in older patients (C65 years) with T2DM [41] . At 24 weeks, the differences in adjusted mean changes from baseline in HbA1c with saxagliptin 2.5 and 5 mg/day vs placebo were similar in patients C65 years of age (-0.60% and -0.55%, respectively) compared with those \65 years of age (-0.56% and -0.67%). In addition, the changes from baseline in FPG and 120-min PPG compared with placebo were similar for the 2 age groups. 
Overall Summary of Efficacy
Results from these clinical trials demonstrate that saxagliptin is effective in improving glycemic control in a broad range of patients, including those early in the course of their disease as well as those with more advanced disease. In a preliminary analysis, baseline patient characteristics most closely associated with a response to saxagliptin (HbA1c decrease C0.5%) included higher HbA1c, higher HOMA-2b, lower fasting insulin concentration, shorter T2DM duration, and male sex [44] .
Safety and Tolerability
In clinical trials, saxagliptin was generally well tolerated, with the incidence of AEs and SAEs similar to placebo or comparator (Table 2) .
Across clinical trials, the most commonly reported AEs included nasopharyngitis, upper respiratory tract infection, diarrhea, urinary tract infection, and headache. Discontinuations from the clinical trials as a result of an AE or SAE were also infrequent with saxagliptin and similar to placebo or comparator (Table 2) . hospitalization for heart failure, hospitalization for coronary revascularization, or hospitalization for unstable angina. The primary end point occurred in a similar proportion of patients receiving saxagliptin (7.3%) or placebo (7.2%) [hazard ratio (HR; 95% CI) for saxagliptin vs placebo, 1.00 (0.89, 1.12); P = 0.99; Table 4 ], indicating that saxagliptin neither increased nor decreased the rate of ischemic events in these patients. Results were similar for the secondary end point (12.8% vs 12.4%; HR, 1.02; 95% CI, 0.94, 1.11; P = 0.66). However, in an analysis of the individual components of the secondary end point, more patients in the saxagliptin group than in the placebo group were hospitalized for heart failure [3.5% vs 2.8%; HR, 1.27 (1.07, 1.51); P = 0.007]. The increased risk of hospitalization for heart failure with saxagliptin was highest among patients with a high overall risk of heart failure (previous heart failure, chronic kidney disease, or elevated concentrations of N-terminal pro-brain natriuretic peptide) [47] . The relative risk of hospitalization for heart failure with saxagliptin was similar in patients with baseline estimated glomerular filtration rates [50, 30 to 50, and \30 mL/min/1.73 m 2 [48] .
The reason for the increase in hospitalization for heart failure with saxagliptin in SAVOR is not clear [46] . Recent meta-analyses of randomized clinical trials [49] and a US insurance claims database [50] suggest that DPP-4 inhibitors may be associated with an increased risk of heart failure in patients with T2DM, [49] or with an increased risk of heart failure-associated hospitalization in patients with T2DM and preexisting heart failure [50] . However, other observational studies suggest no increased risk of hospitalization for heart failure with saxagliptin compared with sitagliptin [51] or with DPP-4
inhibitors as a class compared with other antidiabetes drugs [51, 52] . 
Pancreatitis
The potential association of incretin-based therapies with pancreatitis and pancreatic cancer has been widely debated [57] [58] [59] .
Although some studies have reported an increased risk for pancreatitis or pancreatic cancer with GLP-1 receptor agonists and DPP-4 inhibitors [60, 61] , other studies have not supported this conclusion [62, 63] Across clinical trials, the overall AE profile of saxagliptin was similar to that of placebo; treatment with saxagliptin was associated with a low risk of hypoglycemia and a neutral effect on weight. The improvement in glycemic control seen at 24 weeks of treatment with saxagliptin was maintained for up to 4 years, and the long-term overall safety and tolerability of saxagliptin were similar to that in shorter-term studies. Saxagliptin improved glycemic control in older patients as well as in patients with CV disease or with CV disease risk factors. In a large CV outcomes study that enrolled patients with established CV disease or with multiple CV disease risk factors (SAVOR), saxagliptin did not increase or decrease the rate of ischemic events. However, the rate of hospitalization for heart failure was increased with saxagliptin compared with placebo in SAVOR. Thus, the overall positive clinical profile for saxagliptin needs to be tempered by the observation of an increased risk of hospitalization for heart failure observed in SAVOR. The reasons for this increase in hospitalizations for heart failure are not clear and no specific mechanism has been identified. Additional evaluation of heart failure events and the potential mechanisms involved are needed to provide additional data on how best to manage patients with T2DM who are also at risk for heart failure. 
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